Search
Solifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigationalSolifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
Categories: Drugs for Urinary Frequency and IncontinenceAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[A235720] Although aducanumab's approval represents the first drug treatment for Alzheimer's disease, the approval is conditional on further results. … [L34393] In January 2024, Biogen announced that the development and commercialization of aducanumab will be discontinued to prioritize the marketing of [lecanemab], another drug approved for the treatment
P2X purinoceptor 4
go.drugbank.com/bio_entities/BE0005793TargetHumansPromotes the differentiation and activation of Th17 cells via expression of retinoic acid-related orphan receptor C/RORC (PubMed:35165166).
Synonyms: ATP receptor, Purinergic receptorP2Y purinoceptor 1
go.drugbank.com/bio_entities/BE0009816TargetHumansReceptor for extracellular adenine nucleotides such as ADP (PubMed:25822790, PubMed:9038354, PubMed:9442040).
Synonyms: ADP receptor, Purinergic receptorFunction: A1 adenosine receptor bindingTrichophyton rubrum
go.drugbank.com/drugs/DB10915ApprovedTrichophyton rubrum is a fungus which can provoke allergic reactions. Trichophyton rubrum extract is used in allergenic testing.
Mixtures: Trichophyton for Intradermal Skin TestingClostridium tetani
go.drugbank.com/drugs/DB09876ApprovedInvestigationalMixtures: Td-pur für Erwachsene und HeranwachsendeHaemagglutinin-strain B
go.drugbank.com/drugs/DB15482ApprovedInvestigationalMixtures: Influvac Suspension for InjectionAtibuclimab
go.drugbank.com/drugs/DB06546InvestigationalAtibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.
Methoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnCurrently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. … (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]
Baxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalOn May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia